These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18263560)

  • 1. Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration.
    Bojke L; Claxton K; Sculpher MJ; Palmer S
    Med Decis Making; 2008; 28(1):33-43. PubMed ID: 18263560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
    Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
    Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.
    Ra H; Song LD; Choi JA; Jee D
    PLoS One; 2018; 13(10):e0206690. PubMed ID: 30379971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.
    Hoomans T; Fenwick EA; Palmer S; Claxton K
    Value Health; 2009; 12(2):315-24. PubMed ID: 18657098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.
    Hopley C; Salkeld G; Wang JJ; Mitchell P
    Br J Ophthalmol; 2004 Apr; 88(4):450-4. PubMed ID: 15031152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of screening for oral cancer in primary care.
    Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
    Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaussian process metamodeling in Bayesian value of information analysis: a case of the complex health economic model for breast cancer screening.
    Rojnik K; Naversnik K
    Value Health; 2008; 11(2):240-50. PubMed ID: 18380636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using value of information analysis to inform publicly funded research priorities.
    Ginnelly L; Claxton K; Sculpher MJ; Golder S
    Appl Health Econ Health Policy; 2005; 4(1):37-46. PubMed ID: 16076237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C; Salkeld G; Mitchell P
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability, benefit and costs of early screening for hearing disability: a study of potential screening tests and models.
    Davis A; Smith P; Ferguson M; Stephens D; Gianopoulos I
    Health Technol Assess; 2007 Oct; 11(42):1-294. PubMed ID: 17927921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hybrid cohort individual sampling natural history model of age-related macular degeneration: assessing the cost-effectiveness of screening using probabilistic calibration.
    Karnon J; Czoski-Murray C; Smith KJ; Brand C
    Med Decis Making; 2009; 29(3):304-16. PubMed ID: 19129156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.